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BACKGROUND: Few studies have been published on liver resection alone or in combination with
cytoreductive surgery for liver metastases of ovarian carcinoma.
METHODS: Eight patients who underwent liver resection for metastasis of ovarian cancer were included
in the study. Total abdominal hysterectomy and bilateral salpingo-oophorectomy had been performed
before liver surgery in all patients. The demographic data, follow-up details before and after liver resec-
tion, histopathology of the primary ovarian cancer, type of surgery and outcome were evaluated.
RESULTS: The mean age of the patients was 56.1 (46–68) years. The mean hospitalization time was 
8 (7–10) days. The mean disease-free interval was 5.38 years from the time of initial surgery to surgery 
for metastatic liver lesions, and 39 months after liver resection to secondary metastases. Four patients
did not have any evidence of disease after liver surgery. 
CONCLUSION: Indications for liver resection should be considered in selected patients who have a lim-
ited extent of metastatic disease from ovarian carcinoma. Liver resection for metastases of ovarian carci-
noma could be an effective and feasible approach. [Asian J Surg 2010;33(2):83–8]
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Introduction
Many cancer patients suffer from liver metastasis in the
course of different types of cancer. Resection of liver
metastases of colorectal and neuroendocrine tumours has
gained wide acceptance because the removal of the metas-
tases is associated with improved survival.1 It has been
reported that the 5-year survival rate after surgery for liver
metastases of colorectal cancer varies from 16% to 61%
depending on patient selection. The 5-year survival rate
can reach 76% with surgical resection of hepatic neuroen-
docrine metastases.2,3 However, the resection of liver metas-
tases of noncolorectal, non-neuroendocrine (NCNN)
tumours is a still a matter of debate. The heterogeneity of
these tumours is a major cause of hesitation in deciding
on resection of each technically resectable metastasis, given
that the biological behaviour and survival of this subset
are unclear. Indications for resection of NCNN liver metas-
tases are not well defined.4
Surgical therapy is the major treatment option for
ovarian carcinoma. Even though tumour-free resection is
preferable, cytoreductive surgery might also be performed
before chemotherapy or radiotherapy if complete removal
of the tumour cannot be achieved. Primary cytoreductive
surgery is considered the cornerstone of initial manage-
ment but its role is less clear in recurrent disease.5 Surgi-
cal resection of liver metastases related to gynaecological
malignancies is a new entity under investigation, and 
a limited number of studies have been reported to date.
In this study, we analyzed the preliminary follow-up
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results of patients who underwent liver resection for
metastases of ovarian carcinoma.
Patients and methods
Eight patients who underwent liver resection for metastasis
of ovarian cancer in the Hepato-Pancreato-Biliary Surgery
Unit, Department of General Surgery, Cerrahpasa Medical
Faculty, Istanbul University, between March 2003 and
February 2008 were included in the study. The patients
were followed up until June 2009. The patients had a pre-
operative diagnosis of metastatic ovarian cancer and their
follow-up and therapy regimens were performed by the
Departments of Gynecological Oncology and Medical
Oncology. Liver and regional lymph nodes were the pri-
mary metastatic sites in all patients, and there were no
other metastases at other distant locations such as the
lungs, bone or brain. Medical fitness of the patients was
suitable for major laparotomy. The patients who had dis-
seminated liver metastases or hilar tumour invasion were
not considered for liver resection. Total abdominal hys-
terectomy, bilateral salpingo-oophorectomy and omen-
tectomy had been performed before liver surgery in all
patients. The type of operation and postoperative strategy
were planned by a council that was composed of gynaecol-
ogical oncologists, hepatobiliary surgeons and medical
oncologists, and the patients consented to the decision
taken. The primary and secondary surgery and chemother-
apy planning was as follows.
After primary surgery (total abdominal hysterectomy
or bilateral salpingo-oopherectomy) for ovarian cancer,
the patients received sequential intravenous paclitaxel
(175 mg/m2) and carboplatin (area under the curve, 5 mg ×
min/mL) on day 1 every 3 weeks for six or eight cycles. The
number of cycles was determined according to the re-
sponse to chemotherapy and the general health status of
the patients. When the hepatic metastases were diagnosed
during the follow-up period, liver surgery was performed.
After liver resection for the metastases of ovarian carci-
noma, platinum-based combination regimens were pre-
ferred. The same chemotherapy regimen, which had been
administered as first-line chemotherapy, was adminis-
tered to the patients after liver surgery for eight cycles.
The patients who had no evidence of disease did not re-
ceive any additional treatment after second-line chemother-
apy and proceeded to follow-up. However, the patients
who developed disseminated and unresectable metastatic
lesions after second-line chemotherapy, received additional
second-line regimens including topotecan, liposomal doxo-
rubicin and weekly paclitaxel plus gemcitabine.
The demographic data, follow-up details before and
after liver resection, site and pathology of the primary
ovarian cancer, type of surgery, and outcome were evalu-
ated. All the procedures in the study were followed in
accordance with the ethical standards of the responsible
committee on human experimentation and with the
Helsinki Declaration of 1975, as revised in 1983.
Results
Eight patients underwent liver surgery for metastatic
ovarian cancer. All of the patients had metachronous
lesions. The mean age of the patients was 56.1 (46–68)
years. The demographics, operations and outcomes of the
patients are presented in Table 1. The mean disease-free
interval was 5.38 years from the time of initial surgery to
surgery for metastatic liver lesions, and 39 months after
liver resection to secondary metastases.
There was no tumour left in the remnant liver pa-
renchyma and no macroscopic tumour left in the abdom-
inal cavity (Figure 1). The mean hospitalization time was
8 days (range: 7–10 days). There was no mortality or mor-
bidity in the early postoperative period. The patients
received chemotherapy after liver surgery. Postoperative
follow-up was performed by the outpatient unit of the
Departments of Gynecologic Oncology and Medical On-
cology. Four patients did not have any evidence of disease
after liver surgery until June 2009 (patients 3, 4, 5 and 7).
One patient died because of sudden cardiac arrest at 
7 months after liver surgery (patient no. 1). Another patient
(patient no. 2) died 3 years after surgery, because of mul-
tiple distant organ metastases.
Discussion
Surgical treatment of recurrent ovarian carcinoma is con-
troversial. Cytoreductive surgery is defined as the corner-
stone of management during initial surgery, and it has
been suggested that secondary cytoreduction has a sur-
vival benefit in selected platinum-sensitive patients. Most
authors have found beneficial effects of secondary cytore-
duction for patients with recurrent ovarian cancer.5–7
Cytoreductive surgery has been reported to be more effi-
cient than chemotherapy, hormone therapy, or intraarterial
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chemoembolization.8 The beneficial effects of secondary
cytoreduction are also related to the site of recurrence and
disease-free interval. In patients whose disease-free interval
is long, secondary cytoreduction is more advantageous
than in those who develop carcinomatosis early after
completing primary treatment.5 It has been suggested
that the objective of secondary cytoreduction should be
to achieve residual tumour that measures 0.5 cm, in pa-
tients who are able medically to tolerate a major surgical
procedure.5 Secondary cytoreduction is not recommended
in patients who have a disease-free interval < 12 months,
with evidence of peritoneal carcinomatosis.5 A long disease-
free interval (5.38 years in our study) is an indicator of
good biological tumour behaviour, and we believe that
such patients are good candidates for secondary surgery.
Surgery is the only potentially curative therapy 
for most metastatic cancers to the liver.9 Liver resection
for liver metastases of colorectal and neuroendocrine
tumours is widely performed but liver resection for the
metastases of NCNN origin is still under investigation.9–11
In selected patients, the survival rates following resection
of NCNN liver metastasis (36% at 5 years) are similar to
those for colorectal liver metastases in specialized centres.4
Tumour-free resection margins affect disease-free and
cancer-specific survival, and complete resection of liver
metastases is necessary except for certain selected neu-
roendocrine and testicular tumours.5,8,12,13 Then again,
the cytoreduction rationale for surgery of ovarian carci-
noma makes liver resection a logical approach. The dis-
ease-free interval has exceeded 36 months in some studies
of noncolorectal liver metastases.14 Our mean disease-free
interval was 39 months after liver surgery. Late occur-
rence of NCNN metastases confined to the liver has been
suggested as an indicator of better prognosis. Prognosis
of NCNN liver metastases depends on the resectability of
the lesions, presence of extrahepatic disease, and proba-
bly the type of primary tumour.4 These criteria are also
considered for cytoreductive surgery of epithelial ovarian
carcinoma. NCNN liver metastases are occasionally sepa-
rated into diverse categories in terms of type of primary
tumour, such as gastrointestinal, genitourinary, soft tis-
sue and miscellaneous. The 5-year survival of patients
with genitourinary liver metastases might reach 60%.4,14
Conversely, in another study,8 the authors have reported
no 5-year survival with hepatic metastases of ovarian,
endometrial and cervical primary tumours. However,
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Figure 1. (A) Pericaval and periportal lymphadenopathy. 
(B) Pericaval and periportal area after lymphadenectomy. 
(C) Metastatic lesion and resected lymph nodes.
there have been few published studies on liver resection
alone or together with cytoreductive surgery for liver
metastases of different types of female gynaecological
cancers, especially ovarian carcinoma. The results of our
study are promising for this advanced stage of ovarian
carcinoma.
The extent of resection is another matter of debate in
metastatic ovarian cancer patients who are considered for
liver resection. Metastasectomy has been suggested as an
alternative for exenterative surgery or systemic treatment
for a selected group of patients who are not suitable 
for major surgery or systemic chemotherapy.15 Logmans 
et al15 have indicated that not the whole pathway between
primary tumour and metastasis is automatically contam-
inated. They have concluded that metastatic lesions can
be considered an isolated tumour that can be resected as 
a primary malignancy. Radical removal of the primary
tumour, no evidence of other organ involvement, total
resectability of the metastatic tumour(s), and physiological
tolerance of surgery have been suggested as criteria for 
the management and operability of liver metastasis.15,16 The
medical course of our patients was in accordance with the
criteria of cytoreductive surgery and liver resection for
hepatic metastases. Various operations were performed in
our patients, and they were planned in relation to medical
needs and status of the patients. Some additional intra-
abdominal resections such as a tumour resection from
the caecal wall, intra-abdominal tumoural implant exci-
sion, and lymph node dissection were carried out, as other
specialized centres do along with hepatectomy.8 On prin-
ciple, no macroscopic tumour was left in the remnant liver
parenchyma or abdominal cavity. Achievement of micro-
scopically complete tumour resection is also recommended
for liver resection of NCNN metastases.2 Multiple courses
of salvage chemotherapy have been shown to be effica-
cious after cytoreductive surgery for epithelial ovarian
carcinoma.17 Even though the number of our patients
was limited, the results and outcome of our approach
appear hopeful: no early mortality or morbidity; only one
death after 7 months due to cardiac arrest; half of our
patients are disease-free and alive; and the remaining
patients are being followed up and receiving chemother-
apy as indicated. There is no recurrent liver metastasis in
any of our patients.
Isolated ovarian carcinoma liver metastasis is a rare
entity. However, if the disease is confined to the liver, such
patients are candidates for liver resection. Nevertheless,
most of the studies on surgical management of metasta-
tic liver disease assign these patients along with other
NCNN metastases. However, since there is a consensus on
chemosensitivity and the benefits of debulking surgery in
ovarian carcinoma, consideration should be given to the
advantages of liver resection in liver metastases of ovarian
carcinoma. Conversely, indications for liver resection
should be considered in selected patients. The key points
to keep in mind when considering this strategy are the
limited extent of the metastatic disease and the experience
of the treatment centre. Liver resection for metastases of
epithelial ovarian carcinoma could be effective, safe and
feasible. Larger series that focus purely on this subgroup
of patients as well as longer follow-up are needed to reach
a final conclusion.
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